Trial | NCT04473261  Report issue

Title

Efficacy of Iodine Complex Against COVID-19 Patients
Efficacy of Iodine Complex in Mild to Moderate COVID-19 Patients

  • Phase

    Phase 1/Phase 2

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    200
The objective of this study is to measure the effect of Iodine complex in treating the COVID-19 patients to clear viral load of SARS-CoV-2 along with reduction in severity of symptoms and length of hospitalization of patients with COVID-19.
The proposed study is a placebo-controlled, add-on, randomized trial using parallel group designs. This is a close-label and adaptive, multi-centered design with 1:1:1:1 allocation ratio and superiority framework.
Study Started
Jul 14
2020
Primary Completion
Aug 15
2021
Anticipated
Study Completion
Oct 15
2021
Anticipated
Last Update
Jul 07
2021

Drug Iodine Complex

Iodine Complex capsule (200mg) will be given three times a day

Drug Iodine Complex

Iodine Complex syrup form (40ml) will be given three times a day

Drug Placebo

Empty capsule will be given as placebo

  • Other names: capsule

Drug Idoine Complex

Iodine Complex spray form 2 puffs will be given three times a day

Iodine Complex (Capsule form) Experimental

Iodine Complex) capsule (200mg) will be given three times a day

Iodine Complex (Syrup form) Experimental

Iodine Complex syrup form (40ml) will be given three times a day

Standard Care Alone Placebo Comparator

Placebo as empty capsule. Treatment will be given for all 4 arms will be receiving standard care as per version 3.0 of clinical management guidelines for COVID-19 established by the Ministry of National Health Services of Pakistan COVID-19 guidelines of the study setting.

Iodine Complex (Nasal Spray) Experimental

Iodine complex throat spray of 2 puffs three times a day.

Criteria 

Inclusion Criteria:

Positive PCR with mild to moderate disease

Exclusion Criteria:

Allergic to iodine
Any co-morbidity other than hypertension and dietetics
No Results Posted